Generalized Myasthenia Gravis (gMG) is a rare disorder caused by the immune system attacking the body's own healthy cells.
The antibodies in people with gMG attack the area called the neuromuscular junction where the nerves trigger the muscles to work and interrupt the signals between nerves and muscles, which causes muscle weakness.
People who do not respond to available treatments continue to experience significant muscle weakness that makes it difficult to swallow, talk, or engage in simple daily activities like brushing their hair.
Although there is no cure for gMG, management of this disorder has improved over the past 30 years, leading to significantly fewer deaths and better quality of life.
Alexion is studying the safety and efficacy of an investigational medication as a potential therapy for patients with
gMG who have not responded to previous immunotherapy (called “refractory Myasthenia Gravis”).
New clinical studies may help investigators further understand the causes of gMG.
By studying a potential new
treatment for gMG, there is hope for people who have not had lasting improvements from current treatment options.
- NIH: National Institute of Neurological Disorders and Strokes
- Myasthenia Gravis Foundation of America
- Muscular Dystrophy Association (MDA)
- Mayo Clinic: Myasthenia Gravis
- Read more about Alexion and Myasthenia Gravis